Alpha 2.0
Login Register
» Journals » Clin Lung Cancer

Clinical Lung Cancer

Clinical Lung Cancer is a peer-reviewed medical journal that focuses on the diagnosis, treatment, and management of lung cancer. It provides a platform for clinicians, researchers, and healthcare professionals to share their expertise and advancements in the field. The journal covers a wide range of topics including clinical trials, novel therapies, imaging techniques, and supportive care, aiming to improve patient outcomes and contribute to the overall understanding of lung cancer.
Details
Abbr. Clin Lung Cancer
Publisher Elsevier
Start 1999
End Continuing
Frequency Bimonthly, July 2002-
p-ISSN 1525-7304
e-ISSN 1938-0690
Country United States
Language English
Specialties Oncology
Pulmonary Medicine
Metrics
h-index / Ranks: 4802 74
SJR / Ranks: 2603 1263
CiteScore / Ranks: 2600 7.40
JIF / Ranks: 2654 3.6
Recent Articles
1.
Predicting Severe Radiation Pneumonitis in Patients With Locally-Advanced Non-Small-Cell Lung Cancer After Thoracic Radiotherapy: Development and Validation of a Nomogram Based on the Clinical, Hematological, and Dose-Volume Histogram Parameters
Zhang Y, Zhou S, Yan Y, Wu L, Yuan X, Hu M, et al.
Clin Lung Cancer . 2025 Mar; PMID: 40087057
Purpose: This study aimed to investigate the risk factors for severe radiation pneumonitis (RP) after thoracic radiotherapy (RT) in patients with locally advanced non-small cell lung cancer (NSCLC), develop a...
2.
Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers
Gutta R, Teslow E, Jaeger E, Stoppler M, Chao C, Rous F, et al.
Clin Lung Cancer . 2025 Mar; PMID: 40064574
Background: EGFR alterations have significant therapeutic implications in lung cancer (LCa), yet their prevalence and co-mutational patterns in African American populations remain understudied. This study analyzes EGFR-mutant LCa across races...
3.
The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of...
Roisman L, Mann S, Basel A, Marei R, Krayim B, Kornev G, et al.
Clin Lung Cancer . 2025 Mar; PMID: 40064573
Introduction: Despite recent advances in immunotherapy combinations for extensive-stage small cell lung cancer (ES-SCLC), rapid disease progression following chemotherapy discontinuation remains a significant challenge. While the addition of pembrolizumab to...
4.
Brief Report: Real-World Clinical Utility of Next-Generation Sequencing of Circulating Tumor DNA for Patients With Advanced Lung Squamous Cell Carcinoma (SQUIN)
Garcia-Pardo M, Garcia de Herreros M, Laguna J, Gorria T, Lage Y, Gomez A, et al.
Clin Lung Cancer . 2025 Mar; PMID: 40064572
No abstract available.
5.
Outcomes of Segmentectomy With or Without Preoperative Biopsy in Non-Small Cell Lung Cancer (NSCLC)
Alaparthi S, Ho A, Rshaidat H, Whitehorn G, Madeka I, Ishwar A, et al.
Clin Lung Cancer . 2025 Mar; PMID: 40055134
Background: There is a discussion amongst oncologic societies regarding the necessity of preoperative biopsy prior to resection in lung cancer. We aim to examine outcomes of segmentectomy with or without...
6.
Nonbacterial Thrombotic Endocarditis (NBTE) Treated With Crizotinib in Lung Adenocarcinoma Harboring ROS-1 Rearrangement: Two Case Report and Review of Literature
Chamorro-Perez J, Lage Y, Albarran-Fernandez V, Rosero-Rodriguez D, Agudo P, Martinez-Vives P, et al.
Clin Lung Cancer . 2025 Mar; PMID: 40055133
No abstract available.
7.
The Impact of Radiation Dose to Immune Cells in Stage IV Non-Small Cell Lung Cancer in the Era of Immunotherapy
He J, Liu Y, Wang X, Song R, Zhang J, Li B, et al.
Clin Lung Cancer . 2025 Mar; PMID: 40055132
Purpose: Thoracic radiotherapy (RT) is now widely used in the treatment of advanced non-small cell lung cancer (NSCLC) as palliative, consolidative or radical therapy. However, RT adversely impacts the immune...
8.
Genomic Profiling of Driver Gene Alterations in Patients With Non-Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients
Shah M, Noronha V, Patil V, Singh A, Menon N, Goud S, et al.
Clin Lung Cancer . 2025 Mar; PMID: 40050197
Background: The utility of Next-Generation-Sequencing (NGS) in patients of non-small-cell-lung-cancer (NSCLC) has led to an exponential increase in the identification of driver-gene alterations, however, Indian NGS data was lacking. Materials...
9.
Supraclavicular Lymph Node Metastases in Advanced Lung Cancer: Prevalence and Analysis of Demographic, Clinical and Molecular Characteristics
Trisolini R, Cetoretta V, Sotgiu G, Cancellieri A, Puci M, Viscuso M, et al.
Clin Lung Cancer . 2025 Mar; PMID: 40037966
Background: The prevalence of supraclavicular lymph nodes metastases (SNM) in advanced lung cancer has not been systematically evaluated, nor has then been a comparison of demographic, clinical, or molecular characteristics...
10.
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
Barrichello A, Elkrief A, Ricciuti B, Ganta T, Marron T, Wang X, et al.
Clin Lung Cancer . 2025 Feb; PMID: 40021433
Background: Non-small cell lung cancer (NSCLC) patients aged ≥80 years [y] are underrepresented in clinical trials. We evaluated whether age correlates with a distinct immunophenotype or impacts outcomes to first-line...